344
Views
8
CrossRef citations to date
0
Altmetric
Original Research

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male

, , , , &
Pages 3151-3159 | Published online: 03 Sep 2019

References

  • Joelsson B, Johnsson F. Heartburn–the acid test. Gut. 1989;30(11):1523–1525. doi:10.1136/gut.30.11.15232599437
  • Miner P. Relief of symptoms in gastric acid‐related diseases–correlation with acid suppression in rabeprazole treatment. Aliment Pharmacol Ther. 2004;20:20–29. doi:10.1111/j.1365-2036.2004.02162.x
  • Huang J-Q, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med. 1999;72(2–3):181.10780580
  • Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66(2):273–280.12152963
  • Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97(3):575. doi:10.1111/j.1572-0241.2002.05560.x11922549
  • Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005;6(14):2501–2510. doi:10.1517/14656566.6.14.250116259581
  • Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64(10):935–951. doi:10.1007/s00228-008-0538-y18679668
  • Horn J, Howden C. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005;22:20–24. doi:10.1111/apt.2005.22.issue-s3
  • Small RE. Advances in proton pump inhibitor therapy: an immediate-release formulation of omeprazole. Pharmacol Ther. 2005;30:698–715.
  • Howden C. immediate‐release proton‐pump inhibitor therapy–potential advantages. Aliment Pharmacol Ther. 2005;22:25–30. doi:10.1111/j.1365-2036.2005.02709.x16303034
  • McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3(6):553–563.15952097
  • Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–665. doi:10.1111/j.1572-0241.2001.3600_b.x11280530
  • Abdel-Hamid H. Modified PPIs (a search for the better). Al-Azhar Assiut Med J. 2016;14(1):8. doi:10.4103/1687-1693.180455
  • Gardner J, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther. 2002;16(3):455–464. doi:10.1046/j.1365-2036.2002.01158.x11876698
  • Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(7):861–867. doi:10.1046/j.1365-2036.2000.00813.x10886041
  • Missaghi S, Young C, Fegely K, Rajabi-Siahboomi AR. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies. Drug Dev Ind Pharm. 2010;36(2):180–189. doi:10.3109/0363904090346881120070183
  • Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60(8):531–539. doi:10.1007/s00228-004-0804-615349707
  • Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616. doi:10.1111/j.1572-0241.2003.07710.x14687806
  • Benetti C, Flammini L, Vivo V, et al. Esomeprazole immediate release tablets: gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats. J Control Release. 2016;239:203–210. doi:10.1016/j.jconrel.2016.08.03227574989
  • Walker D, Shing RNK, Jones D, Gruss H-J, Reguła J. Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec. PLoS One. 2015;10(2):e0116308. doi:10.1371/journal.pone.011630825706883
  • Tutuian R, Castell D, Xue S, Katz P. The acidity index: a simple approach to the measurement of gastric acidity. Aliment Pharmacol Ther. 2004;19(4):443–448. doi:10.1111/apt.2004.19.issue-414871284
  • Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999;159(7):649–657.10218743
  • Robinson M. current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther. 1999;13:5–10. doi:10.1046/j.1365-2036.1999.00033.x10555603